Skip to content

Clinical effectiveness of variable dosing regimen with intravitreal conbercept for diabetic macular edema: a randomized controlled trial

Clinical effectiveness of variable dosing regimen with intravitreal conbercept for diabetic macular edema: a randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022572
Enrollment
Unknown
Registered
2019-04-17
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic macular edema

Interventions

1:1+prn
2:3+prn
3:3+q2m

Sponsors

Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Diabetic retinopathy due to type 2 diabetes, DME involving the macular center of the affected eye; 2) Vision loss is caused by DME; 3) The subfoveal retinal thickness=300 uevaluated by OCT; 4) The patients aged =18 years, and signd informed consent, to be able to under goes one year follow-up.

Exclusion criteria

Exclusion criteria: 1) Study eyes who had received intravitreal injections of anti-VEGF drugs within 6 months or within 3 months of the contralateral eye; 2) Study eyes who had undergone vitreoretinal surgery within 6 months; 3) Study eyes Received any form of retinal laser treatment within 3 months; 4) Study eyes received YAG laser iris perforation or YAG laser posterior capsulotomy within 1 month; 5) Study eyes received within 3 months Cataract surgery; 6) Study of ocular inflammation or infection; 7) High-risk proliferative diabetic retinopathy in the study eye; 8) Definitive signs of vitreoretinal surgery such as vitreous hemorrhage, traction retinal detachment And macular pre-retinal proliferative membranes; 9) Study of the presence of neovascular glaucoma in the eye, presence of cataract and other opacity of severe interstitial opacity affect the fundus observer; 10) study of the eye glaucoma can not control the intraocular pressure or need to resist glaucoma filtering surgery; 11) the presence of thromboembolic disease For those with a history of ischemic cardiomyopathy or cerebrovascular accident, cerebrovascular accidents or myocardial infarction occurred within 6 months; 12) Pregnancy or breastfeeding women; 13) Patients with uncontrollable hypertension (refers to systolic blood pressure exceeding 160 mmHg) Or diastolic blood pressure greater than 95mmHg); 14) One-year follow-up can not be completed as required; 15) Researchers believe that the need for exclusion.

Design outcomes

Primary

MeasureTime frame
Best corrected visual acuity;OCT;

Countries

China

Contacts

Public ContactHaicheng She

Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University

haicheng_she@163.com+86 13621035030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026